Cognitive declines therapy by iron burden reduction [1]

Archives of Internal Medicine

Volumn 167, Issue 10, 2007, Pages 1098-

  Waugh, William H ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE;

ALZHEIMER DISEASE; COGNITION; HUMAN; IRON CHELATION; IRON OVERLOAD; LETTER; LOW DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 34249694243     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.10.1098-a     Document Type: Letter

References (5)

1. Espeland MA, Henderson VW. Preventing cognitive decline in usual aging. Arch Intern Med. 2006;166:2433-2434.
2. Nunomura A, Castellani RJ, Zhu X, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:631-641.
3. Goodman L. Alzheimer's disease a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Ment Dis. 1953;118:97-130.
4. Cutler P. Iron overload and psychiatric illness. Can J Psychiatry. 1994;39:8-11.
5. Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991;337:1304-1308.